Temporal trends and determinants of COVID-19 vaccine series initiation after recent pregnancy
During the rapid deployment of COVID-19 vaccines in 2021, safety concerns may have led some pregnant individuals to postpone vaccination until after giving birth. This study aimed to describe temporal patterns and factors associated with COVID-19 vaccine series initiation after recent pregnancy in Ontario, Canada. Using the provincial birth registry linked with the COVID-19 vaccine database, we identified all individuals who gave birth between January 1 and December 31, 2021, and had not yet been vaccinated by the end of pregnancy, and followed them to June 30, 2022 (follow-up ranged from 6 to 18 months). We used cumulative incidence curves to describe COVID-19 vaccine initiation after pregnancy and assessed associations with sociodemographic, pregnancy-related, and health behavioral factors using Cox proportional hazards regression to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Among 137,198 individuals who gave birth in 2021, 87,376 (63.7%) remained unvaccinated at the end of pregnancy; of these, 65.0% initiated COVID-19 vaccination by June 30, 2022. Lower maternal age (<25 vs. 30-34 y aHR: 0.73, 95%CI: 0.70-0.77), smoking during pregnancy (vs. nonsmoking aHR: 0.68, 95%CI: 0.65-0.72), lower neighborhood income (lowest quintile vs. highest aHR: 0.79, 95%CI: 0.76-0.83), higher material deprivation (highest quintile vs. lowest aHR: 0.74, 95%CI: 0.70-0.79), and exclusive breastfeeding (vs. other feeding aHR: 0.81, 95%CI: 0.79-0.84) were associated with lower likelihood of vaccine initiation. Among unvaccinated individuals who gave birth in 2021, COVID-19 vaccine initiation after pregnancy reached 65% by June 30, 2022, suggesting persistent issues with vaccine hesitancy and/or access to vaccination in this population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 19(2023), 2 vom: 01. Aug., Seite 2215150 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Török, Eszter [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Birth |
|---|
| Anmerkungen: |
Date Completed 29.06.2023 Date Revised 03.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2023.2215150 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35751484X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35751484X | ||
| 003 | DE-627 | ||
| 005 | 20231226210433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2023.2215150 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM35751484X | ||
| 035 | |a (NLM)37249316 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Török, Eszter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Temporal trends and determinants of COVID-19 vaccine series initiation after recent pregnancy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2023 | ||
| 500 | |a Date Revised 03.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a During the rapid deployment of COVID-19 vaccines in 2021, safety concerns may have led some pregnant individuals to postpone vaccination until after giving birth. This study aimed to describe temporal patterns and factors associated with COVID-19 vaccine series initiation after recent pregnancy in Ontario, Canada. Using the provincial birth registry linked with the COVID-19 vaccine database, we identified all individuals who gave birth between January 1 and December 31, 2021, and had not yet been vaccinated by the end of pregnancy, and followed them to June 30, 2022 (follow-up ranged from 6 to 18 months). We used cumulative incidence curves to describe COVID-19 vaccine initiation after pregnancy and assessed associations with sociodemographic, pregnancy-related, and health behavioral factors using Cox proportional hazards regression to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Among 137,198 individuals who gave birth in 2021, 87,376 (63.7%) remained unvaccinated at the end of pregnancy; of these, 65.0% initiated COVID-19 vaccination by June 30, 2022. Lower maternal age (<25 vs. 30-34 y aHR: 0.73, 95%CI: 0.70-0.77), smoking during pregnancy (vs. nonsmoking aHR: 0.68, 95%CI: 0.65-0.72), lower neighborhood income (lowest quintile vs. highest aHR: 0.79, 95%CI: 0.76-0.83), higher material deprivation (highest quintile vs. lowest aHR: 0.74, 95%CI: 0.70-0.79), and exclusive breastfeeding (vs. other feeding aHR: 0.81, 95%CI: 0.79-0.84) were associated with lower likelihood of vaccine initiation. Among unvaccinated individuals who gave birth in 2021, COVID-19 vaccine initiation after pregnancy reached 65% by June 30, 2022, suggesting persistent issues with vaccine hesitancy and/or access to vaccination in this population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 vaccination | |
| 650 | 4 | |a COVID-19 vaccine series initiation | |
| 650 | 4 | |a birth | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a pregnant | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Dhinsa, Tavleen |e verfasserin |4 aut | |
| 700 | 1 | |a Dimanlig-Cruz, Sheryll |e verfasserin |4 aut | |
| 700 | 1 | |a Alton, Gillian D |e verfasserin |4 aut | |
| 700 | 1 | |a Sprague, Ann E |e verfasserin |4 aut | |
| 700 | 1 | |a Dunn, Sandra I |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Prakesh S |e verfasserin |4 aut | |
| 700 | 1 | |a El-Chaâr, Darine |e verfasserin |4 aut | |
| 700 | 1 | |a Regan, Annette K |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Kumanan |e verfasserin |4 aut | |
| 700 | 1 | |a Buchan, Sarah A |e verfasserin |4 aut | |
| 700 | 1 | |a Kwong, Jeffrey C |e verfasserin |4 aut | |
| 700 | 1 | |a Håberg, Siri E |e verfasserin |4 aut | |
| 700 | 1 | |a Gravel, Christopher A |e verfasserin |4 aut | |
| 700 | 1 | |a Okun, Nannette |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Mark C |e verfasserin |4 aut | |
| 700 | 1 | |a MacDonald, Shannon E |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Barrett, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Fell, Deshayne B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 19(2023), 2 vom: 01. Aug., Seite 2215150 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:2 |g day:01 |g month:08 |g pages:2215150 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2023.2215150 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 2 |b 01 |c 08 |h 2215150 | ||